Skip to main navigation Skip to search Skip to main content

Effect of lipid lowering on new-onset atrial fibrillation in patients with asymptomatic aortic stenosis: the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study

  • Casper N Bang
  • , Anders Greve
  • , Kurt Boman
  • , Kenneth Egstrup
  • , Christa Gohlke-Baerwolf
  • , Lars Valeur Køber
  • , Christoph A Nienaber
  • , Simon Ray
  • , Anne B Rossebø
  • , Kristian Wachtell
    • Rigshospitalet

    Research output: Contribution to journalJournal articleResearchpeer-review

    Abstract

    Lipid-lowering drugs, particularly statins, have anti-inflammatory and antioxidant properties that may prevent atrial fibrillation (AF). This effect has not been investigated on new-onset AF in asymptomatic patients with aortic stenosis (AS).
    Original languageEnglish
    JournalAmerican Heart Journal
    Volume163
    Issue number4
    Pages (from-to)690-696
    ISSN0002-8703
    DOIs
    Publication statusPublished - 2012

    Keywords

    • Aged
    • Aged, 80 and over
    • Anticholesteremic Agents
    • Aortic Valve Stenosis
    • Atrial Fibrillation
    • Azetidines
    • Double-Blind Method
    • Female
    • Heart Ventricles
    • Humans
    • Male
    • Middle Aged
    • Multivariate Analysis
    • Prognosis
    • Simvastatin
    • Stroke
    • Time Factors

    Fingerprint

    Dive into the research topics of 'Effect of lipid lowering on new-onset atrial fibrillation in patients with asymptomatic aortic stenosis: the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study'. Together they form a unique fingerprint.

    Cite this